Researchers at Brigham and Women’s Hospital have developed a safer way to use focused ultrasound to temporarily open the blood-brain barrier* to allow for delivering vital drugs for treating glioma brain tumors — an alternative to invasive incision or radiation.
Focused ultrasound drug delivery to the brain uses “cavitation” — creating microbubbles — to temporarily open the blood-brain barrier. The problem with this method has been that if these bubbles destabilize and collapse, they could damage the critical vasculature in the brain.
To create a finer degree of control over the microbubbles and improve safety, the researchers placed a sensor outside of the rat brain to listen to ultrasound echoes bouncing off the microbubbles, as an indication of how stable the bubbles were.** That data was used to modify the ultrasound intensity, stabilizing the microbubbles to maintain safe ultrasound exposure.
The team tested the approach in both healthy rats and in an animal model of glioma brain cancer. Further research will be needed to adapt the technique for humans, but the approach could offer improved safety and efficacy control for human clinical trials, which are now underway in Canada.
The research, published this week in the journal Proceedings of the National Academy of Sciences, was supported by the National Institutes of Health in Canada.
*The blood brain barrier is an impassable obstacle for 98% of drugs, which it treats as pathogens and blocks them from passing from patients’ bloodstream into the brain. Using focused ultrasound, drugs can administered using an intravenous injection of innocuous lipid-coated gas microbubbles.